Year All20242023202220212020201920182017 Inozyme Pharma Announces Pricing of Initial Public Offering Jul 23, 2020 Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals Jul 17, 2020 Inozyme Pharma Announces Changes to its Board of Directors Jun 16, 2020 Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency May 14, 2020 Inozyme Pharma Expands Medical Leadership Team Nov 14, 2019 Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders Apr 10, 2019 Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union Jul 17, 2018 Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders Jun 13, 2018 Inozyme Pharma Appoints David Thompson, Ph.D. as Senior Vice President and Chief Scientific Officer May 01, 2018 Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone Nov 15, 2017
Year All20242023202220212020201920182017 Inozyme Pharma Announces Pricing of Initial Public Offering Jul 23, 2020 Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals Jul 17, 2020 Inozyme Pharma Announces Changes to its Board of Directors Jun 16, 2020 Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency May 14, 2020 Inozyme Pharma Expands Medical Leadership Team Nov 14, 2019 Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders Apr 10, 2019 Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union Jul 17, 2018 Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders Jun 13, 2018 Inozyme Pharma Appoints David Thompson, Ph.D. as Senior Vice President and Chief Scientific Officer May 01, 2018 Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone Nov 15, 2017
Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency May 14, 2020
Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders Apr 10, 2019
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union Jul 17, 2018
Inozyme Pharma Appoints David Thompson, Ph.D. as Senior Vice President and Chief Scientific Officer May 01, 2018
Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone Nov 15, 2017